Skip to main content
OpenTrials
Not Yet Recruiting

NCT Number: NCT07371702

PERsonalized Mammographic Screening in Norway

The aim of this study is to assess attendance among women invited to additional breast imaging because they were identified as having an increased risk of breast cancer at screening. High-risk women were defined in two studies: Study A; women with high mammographic density, representing approximately 3-5% of screened women, and Study B; women with a false-positive screening result. Women in Study A will be offered an additional screening examination with digital breast tomosynthesis immediately within 6 months after the screening examination. Women in Study B will be offered an additional standard digital mammography examination one year after their initial screening.

Not Yet Recruiting

Trial opening soon.

Get Notified

Key information

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • invited to screening
  • extremely dense breast (Study A) or a false positive screening result (Study B)

Exclusion criteria

  • Opted out or not signed written consent related to the study
  • Women who have opted out from giving us permission to use screening data for quality assurance and research

Treatment and study plan

Primary outcomes

  1. Attendance rate to extra imaging with digital breast tomosynthesis for women with extremely high mammographic density

    Time frame: Women will be invited to the extra examination with DBT within 6 months after index screening mammography.

    Women with extremely dense breasts will be offered an extra examination with DBT within 6 months after index screening mammography. The investigators will assess the attendance rate to this extra examination.

  2. Attendance rate to an additional screening mammography for women with false positive screening result

    Time frame: Women will be invited to the additional screening mammography within 12 months after index screening mammography.

    Women with false positive screening result will be offered an additional screening mammography within 12 months after index screening mammography. The investigators will assess the attendance rate to this additional examination.

Study contacts

Contact information is provided by the study sponsor or research team.

Solveig Hofvind, PhD, professor

CONTACT

[email protected]

+47 406 45 346

Sponsors and collaborators

Lead sponsor

Norwegian Institute of Public Health

Other Gov

Collaborators

  • Norwegian Cancer Society
  • Oslo University Hospital
  • University Hospital, Akershus
  • Vestre Viken Hospital Trust

Registry information

Official study title

PERsonalized Mammographic Screening in Norway; Additional Examination for Women With Increased Risk of Breast Cancer

Acronym: PERMS

Important dates

Study start
2026
Primary completion
2028
Study completion
2033
First posted
Jan 28, 2026
Registry last updated
Jan 29, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.